검색어: subchoondral cystic (영어 - 몰타어)

cystic fibrosis
fibrożi Ċistika

cystic fibrosis patients
pazjenti b'fibrożi ċistika

cystic fibrosis is caused by mutations in the cftr gene.
il-fibrożi ċistika tiġi kkawżata minn mutazzjoni fil-ġene cftr.

people with cystic fibrosis have many symptoms of the disease.
persuni b’fibrożi ċistika għandhom bosta sintomi ta’ din il-marda.

medicines to treat cystic fybrosis (e.g. ivacaftor)
mediċini għall-kura tal-fibrożi ċistika (eż. ivacaftor)

- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis
irkadar tal- marda pulmonari ostruttiva kronika infezzjonijiet bronko- pulmonari f’ fibrożi ċistika jew f’ bronkjektasi pnewmonja

haemoptysis is a complication in cystic fibrosis and is more frequent in adults.
emoptisi huwa kumplikazzjoni ta’ fibrożi ċistika u hija l-aktar komuni fl-adulti.

bacterial lung infection with p. aeruginosa is frequent in cystic fibrosis patients.
infezzjoni batterika tal-pulmun bi p. aeruginosa hija frekwenti f’pazjenti bil- fibrożi ċistika.

kalydeco should only be prescribed by physicians with experience in the treatment of cystic fibrosis.
kalydeco għandu jiġi preskritt biss minn tobba b’esperjenza fil-kura ta’ fibrożi ċistika.

these cystic findings contributed to an approximate 1.5 mm increase in mean endometrial thickness.
dawn iċ-ċesti misjuba kkaġunaw żieda fil-ħxuna medja tal-endometriju ta’ bejn wieħed u ieħor 1.5 mm.

as well as using bronchitol you will normally keep using the other medicines you take for cystic fibrosis.
apparti li tuża bronchitol normalment tibqa’ tuża l-mediċini l-oħrajn li tieħu għal fibrożi ċistika.

exacerbations of chronic obstructive pulmonary disease broncho-pulmonary infections in cystic fibrosis or in bronchiectasis pneumonia
- infezzjonijiet bronko- pulmonari f’ fibrożi ċistika

a third study investigated the effectiveness of kalydeco in patients with cystic fibrosis due to several mutations other than g551d.
it-tielet studju investiga l-effikaċja ta’ kalydeco f’pazjenti bil-fibrożi ċistika minħabba diversi mutazzjoniijiet li mhumiex g551d.

cayston was more effective than placebo at suppressing lung infection caused by p. aeruginosa bacteria in patients with cystic fibrosis.
cayston kien aktar effikaċi mill-plaċebo fis-soppressjoni tal-infezzjoni pulmonari kkaġunata minn batterji p. aeruginosa f’pazjenti li jbatu minn fibrożi ċistika.

broncho-pulmonary infections in cystic fibrosis clinical trials have included children and adolescents aged 5-17 years.
infezzjonijiet bronko- pulmonari f’ fibrożi ċistika provi kliniċi inkludew tfal u adoloxxenti b’ età ta ’ 5- 17- il sena.

doripenem single dose pharmacokinetics after a 4-hour infusion in adults with cystic fibrosis are consistent with those in adults without cystic fibrosis.
il-farmakokinetika b’doża waħda ta’ doripenem wara infużjoni ta’ 4 sigħat f’adulti b’fibrosi ċistika hija konsistenti ma’ dik f’adulti mingħajr fibrosi ċistika.

ionsys must not be used in patients with severe respiratory depression (breathing problems) or with a rare condition called cystic fibrosis.
ionsys ma għandux jintuża f'pazjenti b'dipressjoni respiratorja severa (problemi fit-teħid tan-nifs) jew b'kundizzjoni rari msejħa fibrożi ċistika.

if you/your child are taking other treatments for cystic fibrosis you/your child should take them in the following order:
jekk inti/it-tifel/it-tifla tiegħek qegħdin tieħdu kuri oħra għal fibrożi ċistika inti/it-tifel/it-tifla tiegħek għandkom teħduhom fl-ordni li ġejja:

children and adolescents acute pulmonary exacerbation of cystic fibrosis in children and adolescents (5-17 years) caused by pseudomonas aeruginosa.
tfal u adoloxxenti tħarriex pulmonari akut ta ’ fibrożi ċistika fi tfal u adoloxxenti (5- 17- il sena) ikkaġunati minn pseudomonas aeruginosa.

due to mutations in the cftr gene (see below), chloride movement is reduced in those with cystic fibrosis (cf).
minħabba l-mutazzjonijiet fil-ġene cftr (ara hawn taħt), il-moviment tal-chloride jonqos f’dawk b’fibrożi ċistika (cf).